1. Gropler RJ, Bergmann SR. Myocardial viability — what is the definition? J Nucl Med 1991;32:10–2.
2. Gallagher BM, Fowler JS, Gutterson NI, MacGregor RR, Wan CN, Wolf AP. Metabolic trapping as a principle of radiopharmaceutical design: some factors responsible for the biodistribution of [18F]2-fluoro-2-deoxy-D-glucose. J Nucl Med 1978; 19:1154–1161.
3. Ratib O, Phelps ME, Huang SC, Henze E, Selin CE, Schelbert HR. Positron tomography with deoxyglucose for estimating local myocardial glucose metabolism. J Nucl Med 1982;23:577–586.
4. Phelps ME, Schelbert HR, Mazziotta JC. Positron computed tomography for studies of myocardial and cerebral function. Ann Intern Med 1983;98:339–359.
5. Halama JR, Gratley J, DeGrado TR, Bernstein DR, Ng CK, Holden JE. Validation of 3-deoxy-3-fluoro-D-glucose as a glucose transport analogue in rat heart. Am J Physiol 1984;246:H777–787.